Logo image of GH

GUARDANT HEALTH INC (GH) Stock Fundamental Analysis

NASDAQ:GH - Nasdaq - US40131M1099 - Common Stock - Currency: USD

38.19  -0.98 (-2.5%)

After market: 38.77 +0.58 (+1.52%)

Fundamental Rating

2

Taking everything into account, GH scores 2 out of 10 in our fundamental rating. GH was compared to 102 industry peers in the Health Care Providers & Services industry. GH has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, GH is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

GH had negative earnings in the past year.
In the past year GH has reported a negative cash flow from operations.
GH had negative earnings in each of the past 5 years.
In the past 5 years GH always reported negative operating cash flow.
GH Yearly Net Income VS EBIT VS OCF VS FCFGH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M

1.2 Ratios

The Return On Assets of GH (-30.99%) is worse than 89.22% of its industry peers.
Industry RankSector Rank
ROA -30.99%
ROE N/A
ROIC N/A
ROA(3y)-32.29%
ROA(5y)-25.29%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GH Yearly ROA, ROE, ROICGH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600 -800 -1K

1.3 Margins

Looking at the Gross Margin, with a value of 61.34%, GH belongs to the top of the industry, outperforming 84.31% of the companies in the same industry.
GH's Gross Margin has declined in the last couple of years.
GH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 61.34%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.32%
GM growth 5Y-1.93%
GH Yearly Profit, Operating, Gross MarginsGH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

3

2. Health

2.1 Basic Checks

GH does not have a ROIC to compare to the WACC, probably because it is not profitable.
GH has more shares outstanding than it did 1 year ago.
The number of shares outstanding for GH has been increased compared to 5 years ago.
GH has a worse debt/assets ratio than last year.
GH Yearly Shares OutstandingGH Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
GH Yearly Total Debt VS Total AssetsGH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

Based on the Altman-Z score of -0.87, we must say that GH is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.87, GH is doing worse than 83.33% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -0.87
ROIC/WACCN/A
WACC8.09%
GH Yearly LT Debt VS Equity VS FCFGH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

A Current Ratio of 4.11 indicates that GH has no problem at all paying its short term obligations.
With an excellent Current ratio value of 4.11, GH belongs to the best of the industry, outperforming 93.14% of the companies in the same industry.
GH has a Quick Ratio of 3.76. This indicates that GH is financially healthy and has no problem in meeting its short term obligations.
GH's Quick ratio of 3.76 is amongst the best of the industry. GH outperforms 92.16% of its industry peers.
Industry RankSector Rank
Current Ratio 4.11
Quick Ratio 3.76
GH Yearly Current Assets VS Current LiabilitesGH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

6

3. Growth

3.1 Past

The earnings per share for GH have decreased by -7.84% in the last year.
The Revenue has grown by 28.20% in the past year. This is a very strong growth!
GH shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 28.08% yearly.
EPS 1Y (TTM)-7.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.77%
Revenue 1Y (TTM)28.2%
Revenue growth 3Y25.52%
Revenue growth 5Y28.08%
Sales Q2Q%20.76%

3.2 Future

Based on estimates for the next years, GH will show a very strong growth in Earnings Per Share. The EPS will grow by 21.21% on average per year.
Based on estimates for the next years, GH will show a quite strong growth in Revenue. The Revenue will grow by 19.35% on average per year.
EPS Next Y11.41%
EPS Next 2Y11.55%
EPS Next 3Y11.13%
EPS Next 5Y21.21%
Revenue Next Year21.08%
Revenue Next 2Y21.24%
Revenue Next 3Y22.01%
Revenue Next 5Y19.35%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
GH Yearly Revenue VS EstimatesGH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
GH Yearly EPS VS EstimatesGH Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4 6 -6

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GH. In the last year negative earnings were reported.
Also next year GH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GH Price Earnings VS Forward Price EarningsGH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GH Per share dataGH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.55%
EPS Next 3Y11.13%

0

5. Dividend

5.1 Amount

No dividends for GH!.
Industry RankSector Rank
Dividend Yield N/A

GUARDANT HEALTH INC

NASDAQ:GH (5/28/2025, 8:00:00 PM)

After market: 38.77 +0.58 (+1.52%)

38.19

-0.98 (-2.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)04-30 2025-04-30/amc
Earnings (Next)08-05 2025-08-05/amc
Inst Owners102.32%
Inst Owner Change0.43%
Ins Owners4.63%
Ins Owner Change0.87%
Market Cap4.73B
Analysts84.71
Price Target59.23 (55.09%)
Short Float %6.54%
Short Ratio3.27
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.25%
Min EPS beat(2)-18.05%
Max EPS beat(2)1.54%
EPS beat(4)1
Avg EPS beat(4)-10.27%
Min EPS beat(4)-18.05%
Max EPS beat(4)1.54%
EPS beat(8)4
Avg EPS beat(8)3.19%
EPS beat(12)6
Avg EPS beat(12)1.4%
EPS beat(16)8
Avg EPS beat(16)1.67%
Revenue beat(2)2
Avg Revenue beat(2)2.94%
Min Revenue beat(2)1.97%
Max Revenue beat(2)3.91%
Revenue beat(4)4
Avg Revenue beat(4)5.15%
Min Revenue beat(4)1.97%
Max Revenue beat(4)8.95%
Revenue beat(8)8
Avg Revenue beat(8)4.22%
Revenue beat(12)10
Avg Revenue beat(12)3.07%
Revenue beat(16)12
Avg Revenue beat(16)2.89%
PT rev (1m)4.92%
PT rev (3m)26.24%
EPS NQ rev (1m)-4.23%
EPS NQ rev (3m)-10.51%
EPS NY rev (1m)-0.43%
EPS NY rev (3m)-7.87%
Revenue NQ rev (1m)2.63%
Revenue NQ rev (3m)3.3%
Revenue NY rev (1m)2.94%
Revenue NY rev (3m)4.01%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.11
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.44
EYN/A
EPS(NY)-2.69
Fwd EYN/A
FCF(TTM)-2.46
FCFYN/A
OCF(TTM)-2.2
OCFYN/A
SpS6.25
BVpS-2.02
TBVpS-2.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.99%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 61.34%
FCFM N/A
ROA(3y)-32.29%
ROA(5y)-25.29%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.32%
GM growth 5Y-1.93%
F-Score4
Asset Turnover0.58
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 77.81%
Cap/Sales 4.21%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.11
Quick Ratio 3.76
Altman-Z -0.87
F-Score4
WACC8.09%
ROIC/WACCN/A
Cap/Depr(3y)115.32%
Cap/Depr(5y)203.86%
Cap/Sales(3y)8.54%
Cap/Sales(5y)12.91%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-7.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.77%
EPS Next Y11.41%
EPS Next 2Y11.55%
EPS Next 3Y11.13%
EPS Next 5Y21.21%
Revenue 1Y (TTM)28.2%
Revenue growth 3Y25.52%
Revenue growth 5Y28.08%
Sales Q2Q%20.76%
Revenue Next Year21.08%
Revenue Next 2Y21.24%
Revenue Next 3Y22.01%
Revenue Next 5Y19.35%
EBIT growth 1Y14.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year40.62%
EBIT Next 3Y21.22%
EBIT Next 5Y16.63%
FCF growth 1Y26.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y23.37%
OCF growth 3YN/A
OCF growth 5YN/A